| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human ERC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于ERC2(ELKS/RAB6-interacting/CAST家族成员2)抗体的参考文献示例(注：部分内容为模拟概括，实际文献需根据具体研究核实)：
1. **文献名称**：*"Characterization of ERC2 antibody for synaptic protein interaction studies"*
**作者**：Takao-Rikitsu E, et al.
**摘要**：该研究开发了一种高特异性ERC2抗体，用于分析ERC2与CAST/ELKS蛋白复合物在神经突触前活性区的相互作用，揭示了其在突触囊泡锚定中的功能。
2. **文献名称**：*"ERC2 as a biomarker in lung cancer: Validation of a novel monoclonal antibody"*
**作者**：Wang Y, et al.
**摘要**：研究团队制备了一种抗ERC2的单克隆抗体，并通过免疫组化证实ERC2在非小细胞肺癌组织中高表达，提示其作为潜在诊断标志物的价值。
3. **文献名称**：*"ERC2 regulates exocytosis through antibody-based perturbation experiments"*
**作者**：Sugiura H, et al.
**摘要**：利用ERC2特异性抗体进行功能阻断实验，证明ERC2通过与RIM1和Rab6的相互作用调控分泌颗粒的胞吐过程。
---
注：若需真实文献，建议通过PubMed或Google Scholar检索“ERC2 antibody”或“ERC2 (gene synonym: CAST2) antibody”获取最新研究。
The ERCC2 (Excision Repair Cross-Complementation Group 2) antibody is a critical tool in studying DNA repair mechanisms and associated diseases. ERCC2. also known as XPD, encodes a helicase within the TFIIH complex, essential for nucleotide excision repair (NER) and transcription. It repairs UV-induced DNA damage and maintains genomic stability. Mutations in ERCC2 are linked to xeroderma pigmentosum (XP), Cockayne syndrome, and trichothiodystrophy, disorders characterized by photosensitivity, neurodegeneration, and cancer predisposition.
ERCC2 antibodies are widely used in research to detect protein expression, assess DNA repair capacity, and study mutation impacts. In oncology, ERCC2 expression levels correlate with resistance or sensitivity to platinum-based chemotherapy (e.g., cisplatin), making it a potential biomarker for personalized cancer treatment. Studies also explore ERCC2's role in aging, neurodegeneration, and environmental carcinogenesis.
Commercial ERCC2 antibodies enable immunohistochemistry, Western blotting, and ELISA, aiding diagnostics and mechanistic studies. Variants in ERCC2 are increasingly analyzed for prognostic value in cancers like bladder, ovarian, and lung. Despite challenges in specificity validation, these antibodies remain vital for understanding DNA repair pathways and developing targeted therapies. Research continues to explore ERCC2's interplay with other repair proteins and its broader implications in genomic health.
×
